Ruxolitinib in the Treatment of Polycythemia Vera: Patient Selection and Special Considerations
In a meta-analysis, researchers concluded that ruxolitinib’s place in current practice should be directed toward disease-related symptoms relief after failure of standard treatment.
Journal of Blood Medicine
In The News
American Journal of Managed Care
In The Literature
American Journal of Hematology European Journal of Haematology